Closer insights in which way BLM-related genomic instability could facilitate tumor progression in BS patients, and in therapeutic options may be identified through the identification of the mutational signature(s) of BS-related tumors, which is yet unreported and unfortunately was inconclusive here due to technical problems with DNA degradation. This evidence concerns the gene BLM and neoplasm.